MedWellAI (MWAI) AI Stock Analysis

• Market Cap: $2.58M
• Dividend Yield: N/A
• Average Volume (3M): 4.51K
• Price to Earnings (P/E): ―
• Beta (1Y): 0.46
• Revenue Growth: -85.65%
• EPS Growth: 35.68%
• Country: US
• Employees: 1
• Sector: Financial
• Sector Strength: 70
• Industry: Financial - Capital Markets
• EPS (TTM): N/A
• Shares Outstanding: 6,236,580
• 10 Day Avg. Volume: 2,376
• 30 Day Avg. Volume: 4,515
• PEG Ratio: <0.01
• Price to Book (P/B): -0.81
• Price to Sales (P/S): 3.42
• P/FCF Ratio: -2.17
• Enterprise Value/Market Cap: 1.15
• Enterprise Value/Revenue: 4.28
• Enterprise Value/Gross Profit: 5.04
• Enterprise Value/Ebitda: -1.11
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: N/A
• Number of Analyst Covering: 0
• EPS Forecast (FY): N/A
• Revenue Forecast (FY): N/A

• Rating: 42 Neutral
• Price Target: $0.40 ▼(-45.00% Downside)

The score is primarily constrained by high-risk financials—ongoing losses, negative cash flow, and negative equity—despite TTM revenue growth. Technicals are mixed (negative MACD and below key moving averages, but neutral RSI and high Stoch), and valuation is weakened by a negative P/E with no dividend yield data.

Positive Factors

Revenue Growth

MedWellAI's strong revenue growth indicates successful market penetration and product adoption, which is crucial for long-term business sustainability.

Product and Market Expansion

The focus on AI in healthcare positions MedWellAI to capitalize on industry trends towards digital transformation, enhancing its competitive edge.

Strategic Partnerships

Strategic partnerships expand MedWellAI's market reach and innovation capacity, fostering revenue growth and strengthening its market position.

Negative Factors

Profitability Challenges

Persistent losses highlight operational inefficiencies and hinder financial health, posing risks to long-term sustainability and investor confidence.

Financial Stability

Negative equity indicates potential solvency issues, limiting financial flexibility and increasing risk, which could impact future operations.

Cash Flow Issues

Inability to generate positive cash flow from operations threatens sustainability, as cash is critical for covering expenses and funding growth initiatives.

MedWellAI Business Overview & Revenue Model

Company Description

MedWellAI Inc., through its subsidiary, develops, acquires, operates, and invests in businesses. It provides AI-driven healthcare and wellness solutions. The company also offers a B2B e-commerce platform for distributing pharmaceutical products, particularly GLP medications for weight loss and diabetes management. In addition, it provides an AI-powered ordering system with inventory tracking, smart suggestions, and support for healthcare providers such as wellness clinics, med spas, and corporate wellness facilities. The company was formerly known as Integrated Ventures, Inc. and changed its name to MedWellAI Inc. in June 2025. The company is based in Clearwater, Florida.

How the Company Makes Money

MedWellAI generates revenue through a combination of product sales, subscription-based services, and strategic partnerships. The company licenses its AI-driven software solutions to hospitals, clinics, and other healthcare providers, offering both one-time licensing fees and ongoing subscription models for continuous access and updates. Additionally, MWAI collaborates with pharmaceutical companies and research institutions to develop specialized AI applications, often entering into revenue-sharing agreements or receiving funding for joint projects. The company also benefits from partnerships with healthcare technology integrators who help deploy its solutions across various healthcare settings, expanding its market reach.

MedWellAI Financial Statement Overview

Summary

Despite strong TTM revenue growth (+15.964%), fundamentals remain very weak: ongoing net losses (TTM net income about -3.0M) with deeply negative margins (TTM net margin about -123%), consistently negative operating/free cash flow (TTM OCF and FCF about -0.86M), and persistently negative shareholder equity (about -7.1M) indicating elevated financing and solvency risk.

Income Statement

TTM (Trailing-Twelve-Months) revenue grew strongly (+15.964%), but profitability remains very weak: net losses continue (TTM net income -3.0M) and margins are deeply negative (TTM net margin about -123%). While losses are smaller than the extremely depressed FY2023–FY2024 period, the business is still far from generating operating profits, and revenue has been volatile year to year (sharp contraction from FY2024 to the latest TTM level).

Balance Sheet

The balance sheet is strained by persistently negative shareholder equity (TTM equity about -7.1M), which is a major credit and financing risk signal and makes leverage ratios less meaningful (debt-to-equity is negative due to negative equity). Total debt is moderate (~0.6M TTM), but the combination of small asset base (TTM assets ~0.55M) and negative equity suggests limited financial flexibility and a reliance on external funding to sustain operations.

Cash Flow

Cash generation is weak with negative operating cash flow and negative free cash flow in every recent period (TTM operating cash flow about -0.86M; TTM free cash flow about -0.86M). Free cash flow improved materially versus the large burn in FY2021–FY2022, but it remains negative and has recently deteriorated (TTM free cash flow growth -8.143%). Cash flow does track net losses (free cash flow to net income ~1.02 TTM), indicating losses are not being masked by large non-cash gains, but the company still needs funding to cover ongoing cash burn.

Breakdown	TTM	Dec 2025	Dec 2024	Dec 2023	Dec 2022	Dec 2021
Income Statement
Total Revenue	689.71K	594.77K	5.86M	5.86M	3.86M	6.55M
Gross Profit	585.91K	586.67K	1.93M	1.93M	1.16M	931.01K
EBITDA	-2.65M	-2.87M	-8.61M	-21.59M	1.07M	-21.59M
Net Income	-3.04M	-3.61M	-11.52M	-11.52M	-565.51K	-22.43M
Balance Sheet
Total Assets	549.87K	805.50K	3.94M	6.59M	16.28M	13.36M
Cash, Cash Equivalents and Short-Term Investments	223.22K	401.31K	57.81K	258.00K	490.28K	2.10M
Total Debt	600.30K	604.27K	500.00K	500.00K	385.44K	19.15K
Total Liabilities	7.61M	3.14M	7.81M	7.10M	5.69M	4.40M
Stockholders Equity	-7.06M	-2.50M	-3.87M	-509.88K	10.59M	8.96M
Cash Flow
Free Cash Flow	-861.21K	-937.55K	-4.13M	-3.73M	-9.88M	-19.90M
Operating Cash Flow	-861.21K	-935.31K	-4.13M	-3.43M	55.45K	-1.57M
Investing Cash Flow	247.90K	1.19M	4.17M	4.17M	-2.27M	-9.12M
Financing Cash Flow	0.00	0.00	-243.15K	-243.15K	604.92K	12.78M

MedWellAI Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 0.72
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Positive
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For MWAI, the sentiment is Negative. The current price of 0.72 is above the 20-day moving average (MA) of 0.49, above the 50-day MA of 0.52, and above the 200-day MA of 0.50, indicating a bearish trend. The MACD of -0.01 indicates Positive momentum. The RSI at 38.34 is Neutral, neither overbought nor oversold. The STOCH value of 75.85 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for MWAI.

MedWellAI Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
Sector *	68 Neutral	$18.00B	11.42	9.92%	3.81%	9.73%	1.22%
HIT	65 Neutral	$66.01M	46.22	11.94%	―	55.15%	-22.92%
NVNI	43 Neutral	$16.96M	-0.47	―	―	―	―
CSAI	43 Neutral	$15.71M	-1.73	-216.29%	―	―	―
MWAI	42 Neutral	$2.58M	-0.80	―	―	-85.65%	35.68%
AIXI	39 Underperform	$3.04M	-0.09	―	―	19.01%	44.24%